Ra Pharma to use extra $8.6 million to develop peptide cyclomimetics for HAE
This article was originally published in Scrip
Executive Summary
Ra Pharmaceuticals, a start-up based in Cambridge, Massachusetts, has begun to reveal more about itself, and has raised $8.6 million in the second tranche of a planned $27 million series A round. Ra was incorporated in 2008, and it saw the series A bringing in around $10 million in February 2010. Ra has picked its lead programme: that of hereditary angioedema (HAE), a rare but serious and often fatal disorder of the immune system, and it aims to develop an oral product as opposed to currently available injectable HAE therapies.